PDHA1抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using PDHA1 mouse mAb against HepG2 (1), HL-60 (2),SK-OV-3 (3),PC-3 (4) and PANC-1 (5) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using PDHA1 mouse mAb (green) and negative control (red).    

  
  

The PDHA1 antibody is a crucial tool for studying the pyruvate dehydrogenase complex (PDC), a mitochondrial enzyme essential for cellular energy metabolism. PDHA1 encodes the E1 alpha subunit of PDC, which catalyzes the conversion of pyruvate to acetyl-CoA, linking glycolysis to the tricarboxylic acid (TCA) cycle. This reaction is tightly regulated by phosphorylation/dephosphorylation mechanisms, with PDHA1 serving as a primary regulatory target. Dysregulation of PDHA1 is associated with metabolic disorders, including pyruvate dehydrogenase deficiency (PDHD), a rare genetic disease causing lactic acidosis and neurological impairments, and cancer, where altered PDHA1 expression may promote the Warburg effect (aerobic glycolysis).

PDHA1 antibodies are widely used in research to investigate metabolic reprogramming in cancer, mitochondrial disorders, and diabetes. They enable the detection of PDHA1 protein levels, phosphorylation status (e.g., at Ser293), and subcellular localization via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Both monoclonal and polyclonal antibodies are available, often validated in knockout models to ensure specificity. Commercial antibodies typically undergo rigorous testing for cross-reactivity and batch consistency. Recent studies also explore PDHA1's role in immune responses and neurodegenerative diseases, expanding its therapeutic relevance. Proper validation using tissue-specific controls is critical due to potential isoform cross-reactivity or phosphorylation-dependent epitope masking.